Cancer Vaccine Institute News

The biggest challenge in ovarian cancer isn’t getting to remission - it’s staying there. Recurrence rates are high, especially for advanced disease. Nineteen-year survivor and CVI vaccine recipient Jamie Crase captures that stark reality: “Stage 4 ovarian cancer has a 90-95% chance of recurrence after the initial treatment. The odds were not in my favor.” At the Cancer Vaccine Institute, we are changing the odds in the favor of Jamie and all patients diagnosed with this deadl

For those impacted by ovarian cancer, September is more than just another month. It’s Ovarian Cancer Awareness Month, a time to raise awareness for a disease that remains underfunded and underrecognized, and a moment for patients and families to be truly seen and heard as we push for the breakthroughs they’ve waited far too long for. Ovarian cancer is especially challenging because there are no reliable tests to catch it early. Most people are diagnosed after the disease is a

On the Cancer Research Frontier is a series spotlighting the scientists, doctors, nurses, patients, and philanthropists at the Cancer Vaccine Institute. Join us in meeting the brilliant minds behind our cancer vaccines and immunotherapies as they share their professional journeys and personal stories. For 17 years, Doreen Higgins was often one of the first people participants met when considering a Cancer Vaccine Institute (CVI) clinical trial. Before they made the decision

The first half of 2026 has been an exciting one at the Cancer Vaccine Institute (CVI), and we are proud to share the progress we’ve made in our Midyear Review. We have six clinical trials actively recruiting, with four additional studies opening soon. Our faculty and research teams have been recognized through competitive awards, invited presentations, and impactful scientific publications. These achievements highlight the significance of our work and elevate the visibility o

Research from the Cancer Vaccine Institute and others points to a near-term future in which cancer vaccines will play an instrumental role in managing cancer. Therapeutic cancer vaccines are designed to help the immune system recognize and attack cancer cells. A key part of this response is generating T-cells, immune cells, that specifically recognize cancer proteins and create a cancer-killing immune response. Some T-cells become “memory” T-cells, remaining in the body long